Reduce tremor and involuntary movements

Trial ID
NCT05626608
Official Title
Neuromodulation électrique Continue du Globus Pallidus Dans la Maladie de Parkinson Par l'électrode Directionnelle CARTESIA™
Goal
Reduce tremor and involuntary movements
Phase
NA
Status
RECRUITING
Sponsor
University Hospital, Montpellier
Study Type
INTERVENTIONAL
Enrollment
10 participants
Conditions
Parkinson Disease
Interventions
Classical ring stimulation, Stimulation in directional mode

Plain-Language Summary

Aimed at cutting down disabling tremor and major motor fluctuations or dyskinesias in people with Parkinson's who still respond to levodopa. It compares conventional ring deep brain stimulation to directional stimulation using the CARTESIA™ electrode in the globus pallidus; directional mode steers current toward problem areas to boost symptom control and reduce stimulation side effects, and DBS generally works alongside levodopa and can allow lower medication doses. Looking for adults 18 to 70 with bilateral idiopathic PD for several years, a clear levodopa response (about 30% improvement), significant motor symptoms despite meds, an off‑med UPDRS III score over 25, and who are candidates for bilateral DBS surgery. People with dementia, severe psychiatric illness, MRI or anesthesia contraindications, pregnancy, inability to complete long follow up, or without informed consent are excluded.

Locations

  • Centre Hospitalier Uniersitaire de Montpellier, Montpellier, France, France

Frequently Asked Questions

What is this trial testing?
This trial is studying Classical ring stimulation. Aimed at cutting down disabling tremor and major motor fluctuations or dyskinesias in people with Parkinson's who still respond to levodopa. It compares conventional ring deep brain stimulation to directional stimulation using the CARTESIA™ electrode in the globus pallidus; directional mode steers current toward problem areas to boost symptom control and reduce stimulation side effects, and DBS generally works alongside levodopa and can allow lower medication doses. Looking for adults 18 to 70 with bilateral idiopathic PD for several years, a clear levodopa response (about 30% improvement), significant motor symptoms despite meds, an off‑med UPDRS III score over 25, and who are candidates for bilateral DBS surgery. People with dementia, severe psychiatric illness, MRI or anesthesia contraindications, pregnancy, inability to complete long follow up, or without informed consent are excluded.
Who can participate?
Participants must be between 18 Years and 70 Years.
Where is this trial located?
This trial is recruiting at 1 location.
Does it cost anything to join?
No. There is no cost to participate. Study-related care and treatment are provided at no charge.
How long does the trial last?
This trial is estimated to last approximately 3 years and 6 months.

View on ClinicalTrials.gov